Hansa Biopharma Reports Third Quarter and Interim Year to Date 2026 Financial Results
Key Highlights
- ➤Q3 revenue 143.0 MSEK versus 30.8 MSEK year over year
- ➤SERB transaction delivered a €110 million upfront payment
- ➤Cash and equivalents rose to 1,337.2 MSEK from 252.1 MSEK
- ➤FDA IND submitted for HNSA-5487 in Guillain-Barré syndrome
- ➤First commercial Australian patient received kidney transplant after Idefirix treatment
Expert Statements
Renée Aguiar-Lucander, CEO of Hansa Biopharma
“This was a quarter of strong execution for Hansa. The closing of the SERB transaction has strengthened our financial position and sharpened our strategic focus as we prepare for the potential US launch of imlifidase, subject to approval, while continuing to advance HNSA-5487 in GBS. We enter the final part of the year with clear priorities, strong momentum and increased flexibility to execute on our next phase of growth.”
Hansa Biopharma AB* Closing of the €115 million licensing transaction with SERB * Cash and cash equivalents amounted to 1,337.2 MSEK as of 30 September 2026 * The first commercial patient in Australia received a living-donor kidney transplant following treatment with Idefirix (Imlifidase) Lund, Sweden, November 11, 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced its interim report for the three and nine months ended September 30, 2026.
Renée Aguiar-Lucander, CEO, Hansa Biopharma, said, “This was a quarter of strong execution for Hansa. The closing of the SERB transaction has strengthened our financial position and sharpened our strategic focus as we prepare for the potential US launch of imlifidase, subject to approval, while continuing to advance HNSA-5487 in GBS. We enter the final part of the year with clear priorities, strong momentum and increased flexibility to execute on our next phase of growth.”
Get started
Create a free account to read the full story.